Year None2022202120202019201820172016201520142013 May 13 View HTML version View PDF Version High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair May 4 View HTML version View PDF Version Regeneron Reports First Quarter 2022 Financial and Operating Results May 2 View HTML version View PDF Version Regeneron Announces Investor Conference Presentations Apr 19 View HTML version View PDF Version Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Apr 14 View HTML version View PDF Version U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19 Apr 7 View HTML version View PDF Version Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation Apr 5 View HTML version View PDF Version Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022 Apr 4 View HTML version View PDF Version FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis Mar 26 View HTML version View PDF Version Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis Mar 15 View HTML version View PDF Version Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation Current page 1 Page 2 Page 3 Next page › Last page »